Antibody Therapeutics : Impact Factor & More
eISSN: 2516-4236
Open AccessShare this on:
Key Metrics
CiteScore 
5
SJR
Q3Immunology
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Antibody Therapeutics
Antibody Therapeutics Journal Specifications
Indexed in the following public directories
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | Oxford University Press |
| Language | English |
| Article Processing Charges | GBP 1750 | USD 2625 |
| Publication Time | 8 |
| Editorial Review Process | Blind peer review |
| General Details | |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Antibody Therapeutics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Antibody Therapeutics
The evolving landscape of enzymatic technologies for precision synthesis of antibody-drug conjugates.
- 1 Jul 2026
- Antibody therapeutics
Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics.
- 1 Jul 2026
- Antibody therapeutics
Cytotoxic activity and safety characterization of IMV-M™, a MUC16×DR5 bispecific antibody.
- 1 Jul 2026
- Antibody therapeutics
Integrating fab phage and yeast display through seamless transfer of paired heavy- and light-chain libraries for efficient antibody discovery.
- 1 Jul 2026
- Antibody therapeutics
Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers.
- 1 Jul 2026
- Antibody therapeutics
Anti-ANGPTL3 antibody and IL-22 fusion protein mitigates nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression
- 16 Jun 2026
- Antibody Therapeutics
The evolving landscape of enzymatic technologies for precision synthesis of antibody-drug conjugates.
- 1 Jul 2026
- Antibody therapeutics
Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics.
- 1 Jul 2026
- Antibody therapeutics
Cytotoxic activity and safety characterization of IMV-M™, a MUC16×DR5 bispecific antibody.
- 1 Jul 2026
- Antibody therapeutics
Integrating fab phage and yeast display through seamless transfer of paired heavy- and light-chain libraries for efficient antibody discovery.
- 1 Jul 2026
- Antibody therapeutics
Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers.
- 1 Jul 2026
- Antibody therapeutics
Anti-ANGPTL3 antibody and IL-22 fusion protein mitigates nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression
- 16 Jun 2026
- Antibody Therapeutics
FAQs on Antibody Therapeutics
How many articles did Antibody Therapeutics publish last year? 
What is Citescore for Antibody Therapeutics?
What is the SJR for Antibody Therapeutics?
Who is the publisher of Antibody Therapeutics?
